Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) hosted a virtual Oncology R&D Day on December 15, 2021, covering advancements in their therapeutic pipeline.
Key updates included:
- 2022 clinical strategy and corporate outlook by CEO Patrick Amstutz.
- Status of Abicipar, an anti-VEGF treatment update by COO Michael Stumpp.
- Technological advancements in DARPin therapeutics.
- Emerging treatments for AML presented by university professors.
The event highlighted continued progress despite COVID-19, including a new collaboration with Novartis.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced a collaboration with Novartis to develop DARPin-conjugated radioligand therapies (DARPin-RLTs) aimed at cancer treatment. Under the deal, Novartis will pay $20 million upfront, with potential milestone payments totaling up to $560 million and low double-digit royalties on sales. This collaboration combines Molecular Partners’ expertise in DARPin technology with Novartis’ capabilities in radioligand therapy, promising targeted delivery of radiation to tumor cells.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has confirmed that its therapeutic, ensovibep, maintains high neutralizing potency against the Omicron variant of SARS-CoV-2 in laboratory studies. This drug, part of a global Phase 2-3 study (EMPATHY) in collaboration with Novartis, has shown remarkable efficacy against prior variants as well, demonstrating an IC50 in the single-digit ng/ml range. The unique tri-specific mechanism of ensovibep is designed to effectively counter mutational burdens, promising a competitive edge against future viral variations.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a biotech firm focusing on DARPin therapeutics, announced upcoming events to showcase its oncology portfolio. Presentations will include MP0317 at ESMO Immuno-Oncology, highlighting its potential for tumor-localized immune activation, and MP0533 at ASH, aimed at acute myeloid leukemia with a unique targeting mechanism. An Oncology R&D Day is scheduled for December 15, 2021, to review the company’s strategies and candidate designs. These events aim to enhance understanding of their therapeutic approaches.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) presented promising results from its Phase 2a study of ensovibep, a treatment for mild to moderate COVID-19. All 12 patients showed reduction in viral load and achieved complete clinical symptom recovery. The drug demonstrated a favorable pharmacokinetic profile and was well tolerated without any significant adverse effects. The ongoing EMPATHY Phase 2-3 study aims to evaluate ensovibep's effectiveness in ambulatory patients, with topline data expected in early 2022, highlighting its potential against evolving variants.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced a research collaboration with experts from the University of Bern to advance its acute myeloid leukemia (AML) candidate, MP0533. This innovative candidate targets three tumor-associated antigens and engages T cells via CD3 for enhanced specificity against AML cells. Preclinical results suggest MP0533 is highly specific and potentially safe for patients, particularly older individuals. The collaboration aims to leverage advanced AML methodologies and the researchers' expertise to explore MP0533's efficacy against therapy-resistant leukemia stem cells.
Molecular Partners announced that its antiviral drug, ensovibep, retains effectiveness against the newly identified Omicron variant of SARS-CoV-2, maintaining potency against key mutations. Ongoing testing on the full Omicron variant has commenced, with results expected soon. The company is conducting the global Phase 2-3 EMPATHY clinical study aimed at evaluating ensovibep's efficacy in treating early-stage COVID-19 patients. Topline phase 2 data is anticipated in early 2022, enhancing confidence in ensovibep as a viable treatment against emerging variants.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced participation by CEO Patrick Amstutz, Ph.D., in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 8:00 AM EST. The presentation will be webcasted and available on the company’s website. Molecular Partners focuses on developing DARPin therapeutics for various diseases, including oncology and infectious diseases, partnering with leading pharmaceutical companies to enhance clinical and preclinical development.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that the Data and Safety Monitoring Board (DSMB) has recommended halting the recruitment of patients for the ensovibep arm in the ACTIV-3 COVID-19 clinical study for hospitalized patients, as it did not meet required futility thresholds. While ensovibep remains well-tolerated, the study highlights challenges in demonstrating efficacy in late-stage COVID-19. Meanwhile, the ongoing EMPATHY study is assessing ensovibep's efficacy in non-hospitalized patients, with topline data anticipated in early 2022.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has initiated a Phase 1 clinical trial for MP0317, its second immuno-oncology DARPin candidate. This therapy aims to deliver tumor-localized immune activation while minimizing systemic toxicity, a common issue with existing CD40-targeting agents. Preclinical results indicate MP0317 can activate immune cells effectively within tumors. The open-label study will enroll up to 30 patients across six cohorts in Europe, assessing safety, tolerability, and pharmacodynamics. The innovative DARPin technology may enhance the efficacy of cancer immunotherapies while protecting healthy tissue.